Psyence Biomedical Ltd. (PBM) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

+206.3%

$9.74

vs $3.18 price

Levered DCF

$9.59

After debt service

Piotroski score

3 / 9

Weak

Altman Z-score

-6.25

Distress zone

Rating

—

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
P/E	-0.2×	14.16×	-457.45×	-47,229.99×	111,852.73×	0×
P/B	0.08×	2.13×	-2,132.9×	4,036.92×	3,861.04×	0×
P/S	0×	0×	0×	0×	0×	0×
EV / EBITDA	0.88×	7.98×	-458.13×	91,719.89×	86,370.64×	0×
Gross margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	14.62×	11.04×	0.09×	0.08×	5.59×	48.5×
Debt / equity	0×	0×	-0.95×	0×	0×	0×
Interest coverage	-655.06×	-395.15×	-51.98×	0×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Return on equity	-40.9%	15.1%	466.2%	3.3%	3.5%	0.0%
Return on invested capital	-36.8%	-54.5%	524.5%	-1.8%	-0.1%	0.0%
Return on assets	-39.5%	13.8%	-4518.7%	3.1%	2.5%	0.0%
Free cash flow yield	-636.2%	-26.2%	-0.0%	-0.0%	-0.0%	0.0%
Earnings yield	-510.6%	7.1%	-0.2%	0.0%	0.0%	0.0%
Enterprise value	-$6.1M	$8.2M	$23.4B	$987.7B	$913.7B	-$4.8M
Net debt / EBITDA	1.08×	-5.98×	-0.19×	0.06×	-0.04×	0×
Cash conversion cycle (days)	-15,908	-22,401	-855,244	0	0	0